Clinical Trials
18
Active:5
Completed:6
Trial Phases
4 Phases
Phase 1:5
Phase 2:6
Phase 3:4
+1 more phases
Drug Approvals
3
CIMA_AEMPS:2
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 2
6 (37.5%)Phase 1
5 (31.3%)Phase 3
4 (25.0%)Phase 4
1 (6.3%)ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Phase 3
Recruiting
- Conditions
- Transitional Cell Cancer of Renal Pelvis and Ureter
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 100
- Registration Number
- NCT04620239
- Locations
- 🇺🇸
University of California - Irvine Medical Center, Irvine, California, United States
🇺🇸Keck School of Medicine at USC Medical Center, Los Angeles, California, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Steba Biotech S.A.
- Registration Number
- NCT04225299
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
Completed
- Conditions
- Cancer of the Prostate
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 374
- Registration Number
- NCT04017325
- Locations
- 🇫🇮
Department of Urology-Tampere University Hospital-, Tampere, Finland
🇫🇷Centre Hospitalier Universitaire (CHU), Angers, France
🇫🇷CHRU Hopital Jean Minjoz, Besançon, France
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 23
- Registration Number
- NCT03849365
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU), Angers, France
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
Phase 2
Active, not recruiting
- Conditions
- Localized Prostate Cancer
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT03315754
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found